Archive for fantasy underrated

A few weeks ago, I stole RotoGraphs contributor Joe Douglas’ idea (with his permission) as I pointed out that the “generic” Tommy Pham had provided surprisingly similar offensive production in his career to the “brand name” Michael Conforto. It was a fun exercise, and one that we’re going to do again today.

To set the stage, we’re going to talk about two rookies with outfield eligibility. One receives plenty of attention and hype; the other, not so much. Mr. Generic debuted in 2016 but is still considered a rookie this season, while Mr. Brand Name debuted in 2017. Here’s how they’ve fared so far this year:

The first thing that jumps out is the nearly 100-point difference in BABIP, and the fact that Mr. Generic’s BABIP is perhaps unsustainably high. More about that in a minute.

Read the rest of this entry »

There are 10 qualified starting pitchers with an xFIP under 2.80 in the last 30 days.

Among them are predictable names like Chris Archer (2.52), Clayton Kershaw (2.53), Chris Sale (2.64), Johnny Cueto (2.74), and Zack Greinke (2.76).

The other five aren’t as well known, and therefore, they are more intriguing.

Being in the top 10 xFIP leaderboard for a month is not necessarily a huge accomplishment. However, xFIP has one of the highest correlations with future ERA of all pitching metrics, so it’s among the most relevant numbers to examine when searching for potential breakouts or analyzing the legitimacy of poor or plus performance.

Below is a table sorted by the top 10 qualified starting pitchers in xFIP over the last 30 days*, with the best statistic in each category highlighted in yellow, and the worst statistic in each category highlighted in red: Read the rest of this entry »

As a RotoGraphs reader, I’ve always enjoyed Joe Douglas’s “Buying Generic” series. In past articles, he has compellingly compared “generic” players like Ryon Healy, Logan Forsythe, and Justin Bour to “brand name” ones like Jake Lamb, Jason Kipnis, and Carlos Santana.

The fantasy relevance of the exercise is obvious: Buying generic allows owners to acquire players cheaply and with relative ease, instead of paying a premium (whether in a trade or in a draft or auction) for a brand-name player.

For today’s comparison, we’re going to analyze two players who have played in parts of the last three seasons, but neither has eclipsed 350 plate appearances in any one year. Both appear on their way to full-time jobs in 2017 and beyond.

Here’s how Mr. Generic and Mr. Brand Name have fared since 2015:

Read the rest of this entry »